Aktiechat - investeringstips

	3/11 17:34 af Helge Larsen/PI-redaktør	This session is over.
	3/11 17:33 af Jan Van de Winkel	We look forward to returning for Q4 and thank you for all the great and energizing questions..
	3/11 17:33 af Helge Larsen/PI-redaktør	Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to to seeing you back here on ProInvestor.com after Q4.
	3/11 17:32 af Jan Van de Winkel	We will use the corporate tax rate in Denmark of 22%..
	3/11 17:32 af investor1989	What long term tax rate (when all tax loses are used) should we use for genmab going forward ?
	3/11 17:31 af Jan Van de Winkel	This was to meet our obligations as we had 70,000 RSUs outstanding, this number would also cover near term committments..
	3/11 17:30 af investor1989	You bought back 100.000 shares in Q3. Have you some kind of guiding around that going forward or are that an oppurtunistic thing around the share price etc. ?
	3/11 17:30 af Jan Van de Winkel	Looking forward...
	3/11 17:30 af Helge Larsen/PI-redaktør	Great. We have 2 questions more left for you. :-)
	3/11 17:29 af Jan Van de Winkel	We - and Janssen - vigourously dispute that there is patent infringement and therefore we cannot further comment on the litigation..
	3/11 17:28 af jkj	Regarding the Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States, if Morphosys should be succesful, what will then Genmab obligations ?
	3/11 17:28 af Jan Van de Winkel	There is a lot of interesting data and we have issued a media release highlighting what we think are key abstracts..
	3/11 17:27 af jkj	if you should highligt one off your released abstractat for ash, which one should that be ?
	3/11 17:26 af Jan Van de Winkel	We are entitled to a single digit royalty and milestone payments and we are very pleased to see a blue chip IO player such as BMS actively moving forward with this program..
	3/11 17:25 af GeorgeBest	After BMS bought Cormorant and thereby HuMax-IL8, has that increased your expectations that IL8 can develope into a meaningful earnings contributer to Genmab?
	3/11 17:25 af Jan Van de Winkel	This is a productive collaboration but Novo Nordisk is responsible for updates on active programs..
	3/11 17:24 af Joakim Von And	News on corbaration ( samarbejde ) with Novo ?
	3/11 17:24 af Jan Van de Winkel	This is a preclinical program, run by Lundbeck so we cannot give further information on this program..
	3/11 17:24 af GeorgeBest	When do you expect Lundbeck to move into the clinic with the Alzheimer drug licenced from Genmab?
	3/11 17:23 af Jan Van de Winkel	Next week (at our capital markets day) we will give further clarity on other blood cancer indications..
	3/11 17:22 af Bulder	Is it your intention to take Daratumumab in the clinic against Acute Myeloid Leukemia?
	3/11 17:22 af Jan Van de Winkel	No..
	3/11 17:22 af GeorgeBest	After Novartis stroke a bispecific license deal with Xencor, has that dampened your expectations on Genmabs duobody collaboration with Novartis?
	3/11 17:20 af Jan Van de Winkel	It is of course more challenging to keep 50% or more of the ownership, but not an obstacle..

	3/11 17:19 af GeorgeBest	You have on countless occasions told that Genmab want to keep 50% ownership in new tecknology deals. Is that an obstacle to get new deals concluded?
	3/11 17:19 af Jan Van de Winkel	We cannot comment on specific partnerships..
	3/11 17:19 af Jan Van de Winkel	we will talk more about our technologies at our capital markets day next week..
	3/11 17:19 af GeorgeBest	Is Gilead interested in doing more Duobody/Hexabody license deals, as the ohne they did on HIV?
	3/11 17:18 af Jan Van de Winkel	We have a number of interactions with pharma and biotech companies for different therapeutic areas...
	3/11 17:18 af GeorgeBest	Is there any interest from big pharma in Genmabs hexabody platform? So there is no license collaborations published with big pharma?
	3/11 17:17 af Jan Van de Winkel	Next week we will hold a capital markets day (in NYC but also webcast live and archived on our website). This should shed a lot of light on our preclinical and clinical programs..
	3/11 17:16 af investor1989	The two IND you are targeting for 2017. Can you maybe show some more light on timing. First half, summer, second half. etc?
	3/11 17:15 af Jan Van de Winkel	It is very time consuming and a long process to do deals. We are activating working on the partnering of HexaBody and DuoBody platforms and do expect new agreements in the f uture..
	3/11 17:14 af investor1989	Hexabody partnerships have been slow since this platform was launched. Why that? when launched you talked about inlicense drugs, life cycle management opportunities etc. ?
	3/11 17:14 af Jan Van de Winkel	Contractually Seattle Genetics can exercise their opt in right at the end of the Phase 1/2 study. This study is ongoing..
	3/11 17:13 af Solsen	Mr Winkel. Could you sheed some light on when to expect Seattle Geneticts to decide to co-develope or let Genmab going alone on royalty basis with Tisotumab ?
	3/11 17:13 af Jan Van de Winkel	You can expect combination studies between daratumumab and other key MM agents in the coming time..
	3/11 17:12 af Sukkeralf	Do Janssen intend to start phase III trials with Daratumumab in combination with Kyprolis (and Ninlaro) to cover all proteasome inhibitor combinations (and making a bit harder for isatuximab) to find a place in the CD38 MM-marked ?
	3/11 17:11 af Jan Van de Winkel	...the sub cut version would get a different brand name, and likely a different price but that is determined by Janssen..
	3/11 17:11 af Jan Van de Winkel	this means a royalty between 12-20% of net sales...
	3/11 17:11 af Jan Van de Winkel	The deal between Genmab and Janssen stays the same (exactly the same royalty as with i/v)...
	3/11 17:10 af Sukkeralf	If Janssen get sc dosing of daratumumab (via Halozymes technology) approved - could that lower the royalties Genmabs gets or will Halozymes royalty only be deducted fra Janssen ? Would Darzalex then be prices differently due to better convenience (sc dosing) for the patients ?
	3/11 17:09 af Jan Van de Winkel	..
	3/11 17:09 af Jan Van de Winkel	As the studies have not yet started and immunomodulatory effects take time to build up, you shouldnt expect data in the near future.
	3/11 17:08 af Solsen	Mr Winkel. When can we expect the first in human data on the immunomodulatory effect in solid cancer (Darzalex) ?
	3/11 17:07 af Jan Van de Winkel	This study is announced in a solid tumor and should start shortly.
	3/11 17:06 af Bulder	Any news about dara + Tecentriq in a solid tumor?
	3/11 17:05 af Jan Van de Winkel	We feel that daratumumab is an excellent backbone treatment for MM. And that many new agents would be excellent combination partners with daratumumab..
	3/11 17:04 af MrEbbe	Dear Jan. Congrats, on the great Q3 performance. Could you give us a brief overview of the competitors situations regarding Darzalex. There have been some articles lately with oral tablets among others. How big a thread is these to Darzalex, that takes longer time pr treatment.
	3/11 17:03 af Jan Van de Winkel	There is a Phase 2 study scheduled for NKT Cell Lymphoma by Janssen so we are enthused by this opportunity and look forward to the data.